RxDoctor Payments Data

Rupam Sharan, MD

Gastroenterology · Greensburg, PANPI 1972611309

Payments from drug & device makers

$1,474in general payments, 2019–2025

Across 61 payments — averaging $24.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$755
  • Abbott$101
  • Regeneron Healthcare Solutions, Inc.$99
  • Takeda Pharmaceuticals U.S.A., Inc.$74
  • Pfizer$69
  • Merck$59
  • plus $317 from 11 others

What the payments were for

  • Food & beverage$1,474100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,474 in reported general payments places this provider in the 40th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$74,346
Medicare patients
339
Services billed
604

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab27$265,436
LinzessLinaclotide89$51,712
Mesalamine48$36,546
CreonLipase/Protease/Amylase14$33,598
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates281$19,487
Sucralfate66$11,015
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg221$4,773
MovantikNaloxegol Oxalate12$4,679
Mesalamine ErMesalamine12$4,327
Omeprazole476$4,145
Famotidine259$2,470
Esomeprazole Magnesium24$2,346
Pantoprazole Sodium218$2,306
Lansoprazole16$2,301
ClenpiqSod Picosulf/Mag Ox/Citric Ac13$2,163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$755$85,309103 claims
Ferring Pharmaceuticals Inc.Clenpiq$19$2,16313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 935 gastroenterology providers in Pennsylvania.

Other gastroenterology in Greensburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →